Arcturus Therapeutics (NASDAQ:ARCT) Stock Rating Lowered by Citigroup

Arcturus Therapeutics (NASDAQ:ARCT) was downgraded by research analysts at Citigroup from a “buy” rating to a “neutral” rating in a report released on Thursday, MarketBeat Ratings reports. They currently have a $12.00 target price on the biotechnology company’s stock, down from their prior target price of $49.00. Citigroup’s target price indicates a potential upside of 6.95% from the stock’s current price.

A number of other analysts also recently issued reports on the company. HC Wainwright started coverage on Arcturus Therapeutics in a research report on Thursday, September 4th. They issued a “buy” rating and a $60.00 price target for the company. Leerink Partners lowered their price target on Arcturus Therapeutics from $63.00 to $54.00 and set an “outperform” rating for the company in a research report on Friday, August 22nd. Wells Fargo & Company lowered their price target on Arcturus Therapeutics from $45.00 to $42.00 and set an “overweight” rating for the company in a research report on Tuesday, August 12th. BTIG Research lowered their price target on Arcturus Therapeutics from $48.00 to $23.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Arcturus Therapeutics in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $31.71.

Arcturus Therapeutics Stock Performance

NASDAQ ARCT opened at $11.22 on Thursday. The company has a market capitalization of $304.74 million, a P/E ratio of -5.03 and a beta of 2.39. Arcturus Therapeutics has a one year low of $8.04 and a one year high of $24.17. The stock has a 50 day moving average price of $18.72 and a 200-day moving average price of $14.76.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its earnings results on Monday, August 11th. The biotechnology company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.77. The firm had revenue of $28.30 million during the quarter, compared to the consensus estimate of $17.64 million. Arcturus Therapeutics had a negative return on equity of 24.87% and a negative net margin of 49.26%. As a group, equities analysts predict that Arcturus Therapeutics will post -2.22 EPS for the current fiscal year.

Institutional Trading of Arcturus Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. increased its stake in Arcturus Therapeutics by 9.1% in the first quarter. Goldman Sachs Group Inc. now owns 509,712 shares of the biotechnology company’s stock worth $5,398,000 after purchasing an additional 42,636 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in shares of Arcturus Therapeutics during the first quarter valued at $299,000. Invesco Ltd. increased its stake in shares of Arcturus Therapeutics by 83.1% during the first quarter. Invesco Ltd. now owns 34,896 shares of the biotechnology company’s stock valued at $370,000 after buying an additional 15,836 shares during the period. Jacobs Levy Equity Management Inc. increased its stake in shares of Arcturus Therapeutics by 20.6% during the first quarter. Jacobs Levy Equity Management Inc. now owns 144,141 shares of the biotechnology company’s stock valued at $1,526,000 after buying an additional 24,583 shares during the period. Finally, Y Intercept Hong Kong Ltd bought a new stake in Arcturus Therapeutics during the first quarter valued at about $244,000. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.